[Form 4] Jasper Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vestis Corporation (VSTS) Form 4 filing: On 1 July 2025, Chief Accounting Officer John Laveck was granted 41,119 restricted stock units (RSUs) of Vestis common stock at a purchase price of $0.00.

The RSUs will vest in three equal annual installments beginning on the first anniversary of the grant date (expected 1 July 2026, 2027 and 2028). Following the award, Laveck’s total beneficial ownership stands at 41,119 shares, all held directly. No derivative securities or additional transactions were reported.

The transaction is a routine equity incentive meant to align the newly appointed CAO’s interests with shareholders; it does not involve open-market purchases or sales and therefore has limited immediate market impact.

Positive

• Executive-shareholder alignment: 41,119 RSUs incentivize the CAO to focus on long-term company value.
• No cash outflow: Shares were granted at $0, preserving company liquidity.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine RSU grant to CAO; aligns incentives but minimal short-term valuation impact.

This Form 4 discloses an inaugural equity award of 41,119 RSUs to Vestis’ Chief Accounting Officer, John Laveck. The zero-cost grant, subject to three-year vesting, is standard practice for executive retention and governance alignment. Because shares are not sold into the market and no cash changes hands, dilution is negligible and spread over future periods as the RSUs vest. Investors should view the filing as neutral: it signals normal onboarding compensation rather than insider conviction buying or selling.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nolet Chris

(Last) (First) (Middle)

C/O JASPER THERAPEUTICS, INC.

2200 BRIDGE PKWY, SUITE #102

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc. [ JSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.77	07/03/2025		A		7,500(1)		07/03/2026	07/03/2035	Voting Common Stock	7,500	$0.00	7,500	D

Explanation of Responses:

1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders.

	By: /s/ Herb Cross, as Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Vestis (VSTS) shares did CAO John Laveck acquire?

41,119 restricted stock units were granted to him according to the Form 4.

What is the vesting schedule for the RSUs granted to John Laveck?

They vest in three equal annual installments starting one year after the 1 July 2025 grant date.

What price did John Laveck pay for the shares?

The RSUs were granted at $0.00 per share; no cash payment was required.

How many Vestis shares does the CAO beneficially own after the transaction?

He now beneficially owns 41,119 shares, all held directly.

When was the Form 4 for this insider transaction filed?

The filing was signed and submitted on 3 July 2025.